This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.
Mohammad A. Chaudhary, PhD
Advertisement
Articles by Mohammad A. Chaudhary, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC
2
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
3
Fifth Death Confirmed in NYC Legionnaires' Outbreak
4
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
5